XTX Topco Ltd Reduces Holdings in ESSA Pharma Inc. (NASDAQ:EPIX)

XTX Topco Ltd trimmed its position in shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) by 39.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,829 shares of the company’s stock after selling 14,697 shares during the quarter. XTX Topco Ltd owned 0.05% of ESSA Pharma worth $36,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Tang Capital Management LLC purchased a new position in ESSA Pharma during the fourth quarter worth $7,697,000. Bank of America Corp DE lifted its position in shares of ESSA Pharma by 10,153,775.0% during the fourth quarter. Bank of America Corp DE now owns 812,310 shares of the company’s stock worth $1,454,000 after purchasing an additional 812,302 shares during the last quarter. Two Sigma Investments LP bought a new stake in shares of ESSA Pharma during the fourth quarter worth $378,000. Marshall Wace LLP bought a new stake in shares of ESSA Pharma during the fourth quarter worth $324,000. Finally, BNP Paribas Financial Markets lifted its position in shares of ESSA Pharma by 269.9% during the fourth quarter. BNP Paribas Financial Markets now owns 164,595 shares of the company’s stock worth $295,000 after purchasing an additional 120,100 shares during the last quarter. 75.12% of the stock is owned by hedge funds and other institutional investors.

ESSA Pharma Trading Up 0.5%

NASDAQ:EPIX opened at $1.93 on Friday. ESSA Pharma Inc. has a twelve month low of $1.40 and a twelve month high of $7.88. The company has a market cap of $91.31 million, a price-to-earnings ratio of -3.45 and a beta of 1.55. The stock has a fifty day simple moving average of $1.80 and a 200-day simple moving average of $1.71.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last released its earnings results on Wednesday, August 13th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.08. As a group, equities research analysts predict that ESSA Pharma Inc. will post -0.42 EPS for the current fiscal year.

ESSA Pharma Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.